Corbus Pharmaceuticals (CRBP) announced the dosing of the first participant in the PD-1 combination arm of its Phase 1 study investigating CRB-701 in solid tumors. Participants in this arm of the study are being randomized to the 2.7 mg/kg and 3.6 mg/kg cohorts in combination with Keytruda. The three-part Phase 1 study is evaluating the safety, pharmacokinetics and efficacy of CRB-701 in participants with advanced solid tumors associated with high Nectin-4 expression. The Part A dose escalation of the study evaluated four predetermined doses and is followed by Part B and Part C. The Company expects to provide a data update and establish the recommended Phase 2 dose in the fourth quarter of this year.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRBP:
- Corbus Pharmaceuticals: Strategic Positioning and Promising Pipeline Drive Buy Rating
- Buy Rating for Corbus Pharmaceuticals’ CRB-701: Promising Efficacy and Safety in Oncology
- Corbus Pharmaceuticals Appoints New Chair of the Board
- Corbus Pharmaceuticals appoints Jacques as Chair of Board of Directors
- Corbus Pharmaceuticals price target lowered to $28 from $40 at B. Riley